PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2010; 5(12): e14346.
Published online 2010 December 16. doi:  10.1371/journal.pone.0014346
PMCID: PMC3002941

A Rare Myelin Protein Zero (MPZ) Variant Alters Enhancer Activity In Vitro and In Vivo

Jörg Hoheisel, Editor

Abstract

Background

Myelin protein zero (MPZ) is a critical structural component of myelin in the peripheral nervous system. The MPZ gene is regulated, in part, by the transcription factors SOX10 and EGR2. Mutations in MPZ, SOX10, and EGR2 have been implicated in demyelinating peripheral neuropathies, suggesting that components of this transcriptional network are candidates for harboring disease-causing mutations (or otherwise functional variants) that affect MPZ expression.

Methodology

We utilized a combination of multi-species sequence comparisons, transcription factor-binding site predictions, targeted human DNA re-sequencing, and in vitro and in vivo enhancer assays to study human non-coding MPZ variants.

Principal Findings

Our efforts revealed a variant within the first intron of MPZ that resides within a previously described SOX10 binding site is associated with decreased enhancer activity, and alters binding of nuclear proteins. Additionally, the genomic segment harboring this variant directs tissue-relevant reporter gene expression in zebrafish.

Conclusions

This is the first reported MPZ variant within a cis-acting transcriptional regulatory element. While we were unable to implicate this variant in disease onset, our data suggests that similar non-coding sequences should be screened for mutations in patients with neurological disease. Furthermore, our multi-faceted approach for examining the functional significance of non-coding variants can be readily generalized to study other loci important for myelin structure and function.

Introduction

Myelin protein zero (MPZ) is an integral membrane glycoprotein and a major structural component of peripheral nervous system myelin. MPZ has cell-adhesion properties and forms tetramers that are thought to bind other tetramers on opposing membranes, thus holding concentric layers of myelin intact [1], [2], [3], [4]. The importance of MPZ for proper myelination is underscored by the fact that MPZ protein-coding and splice-site mutations cause demyelinating Charcot-Marie-Tooth disease type 1B (CMT1B) [5], [6], [7]; however, mutations in transcriptional regulatory elements have not been reported to date. The identification of null MPZ alleles in patients with CMT1B suggests that there is a threshold in the amount of MPZ required for proper myelination [8]; in support of this notion, mice that are heterozygous for an Mpz-knockout allele develop a late-onset peripheral demyelinating neuropathy [9]. It is thus reasonable to consider cis-acting regulatory elements as excellent candidates for harboring mutations that affect MPZ transcription.

The regulation of MPZ transcription involves at least two previously described regulatory elements: a proximal promoter and an enhancer located in the first intron [10], [11], [12]. Two transcription factors with known roles in MPZ expression are SRY-box 10 (SOX10) and early growth response 2 (EGR2); indeed, mutations in each of these genes have been shown to cause CMT disease [8], [13]. Other studies have demonstrated that SOX10 and EGR2 bind to the intronic enhancer both in vitro and in vivo, and that mutagenesis of the SOX10-binding sites within this enhancer reduces binding of these transcription factors [11], [14], [15], [16], [17]. Such findings suggest that variants within these SOX10- and EGR2-binding sites may affect MPZ transcriptional regulation. In support of this notion, a CMT-associated mutation has been identified in a SOX10 binding site at the gap junction protein beta 1 (GJB1) locus [18], [19].

We sought to identify and study MPZ variants within evolutionarily conserved SOX10- and EGR2-binding sites. In this study, we report a rare human variant that alters the activity of an MPZ enhancer, a finding that has implications for understanding the transcriptional regulation of MPZ and for assessing the functional significance of non-coding variants within genes implicated in human inherited neuropathies.

Results

Conserved sequences and transcription factor-binding sites within MPZ

We used two approaches to identify evolutionarily conserved sequences [i.e., multi-species conserved sequences (MCSs)] within the MPZ gene. First, we generated and collected sequences of the genomic region encompassing MPZ from multiple species, generated a multi-sequence alignment, and then analyzed that alignment for highly conserved segments. Second, we examined this genomic region on the UCSC Human Genome Browser [20], which contains annotations about evolutionary sequence conservation. These analyses revealed four MCSs of particular interest: MPZ-MCS1, MPZ-MCS2, MPZ-MCS3, and MPZ-MCS4 (Fig. 1A). Because SOX10 and EGR2 play important roles in MPZ expression, we computationally searched for predicted SOX10- and EGR2-binding sites that reside within each MPZ-MCS (see Methods for details). This analysis revealed a total of 14 SOX10- and four EGR2-binding sites in the four MCSs (Table 1). For the experiments described below, each MCS tested directly corresponds to the UCSC Genome Browser coordinates provided in the second column of Table 1.

Figure 1
Analysis of MCSs in the genomic region encompassing MPZ.
Table 1
Transcription factor-binding sites within MPZ MCSs.

Identification of the c.126-1086T>A nucleotide variant in MPZ-MCS3

As part of a larger effort to screen patients with neurological disease for genetic variants, we sequenced the above four MCSs (as well as all MPZ protein-coding regions) in 192 individuals, including 69 patients diagnosed with demyelinating peripheral neuropathy. These efforts revealed one novel variant (c.126-1086T>A) in a heterozygous state within MPZ-MCS3 (which resides in the first intron of MPZ; see Fig. 1A) in one patient from our cohort with congenital non-progressive central nervous system hypomyelination affecting the supratentorial structures, but no signs of demyelinating peripheral neuropathy (BAB1733; Fig. 1B). Importantly, this variant resides within a previously-described SOX10-binding site within MPZ-MCS3 (Fig. 1B, black half-arrows and red box) [11], [16]; dimerized SOX10 proteins are known to bind to head-to-head SOX10-binding sequences [21]. No other variants in the SOX10- and EGR2-binding sites listed in Table 1 were identified in our patient cohort.

The c.126-1086T>A variant is not present in the public SNP database (dbSNP), and we did not detect it in a panel of 514 chromosomes from a North America population. Analysis of additional family members revealed that c.126-1086T>A was inherited from the patient's father. However, the father was not available for clinical evaluation, therefore we are unable to conclude whether or not c.126-1086T>A segregates with disease. Examination of our multi-sequence alignment (Fig. 1C) and that available at the UCSC Human Genome Browser (Fig. 1D) revealed that the affected T nucleotide is extensively (although not fully) conserved among mammalian species. Of note, the two sources of armadillo sequence differed in the nucleotide at this position, being either an A (Fig. 1C) or a T (Fig. 1D); this discrepancy could represent a sequencing error, an alignment error, or a natural variation of this nucleotide in armadillo. These findings indicate that c.126-1086T>A is a rare variant within a non-coding genomic segment that may be important for MPZ function.

c.126-1086T>A is associated with decreased in vitro enhancer activity

We tested each of the four conserved non-coding segments at MPZ (Fig. 1A) for their ability to direct reporter-gene expression (Fig. 2A). This involved cloning each segment upstream of a minimal promoter directing luciferase expression (Fig. 2A), transfecting each into SOX10-positive Schwann (S16) cells, and assessing luciferase activity as a proxy of reporter gene expression compared to a control vector with no insert (pE1b). MCS1 and MCS4 did not display any ability to direct reporter gene expression. In contrast, MCS2 and MCS3 directed reporter gene expression in a manner ~90-fold and ~45-fold higher than the control vector, respectively. Thus, these data confirm the previously-reported activity of the MPZ promoter (MCS2) and intronic enhancer (MCS3) in vitro and in vivo [11], [14], [15], [16], [17], further suggesting that these elements are required for MPZ expression.

Figure 2
Functional characterization of the c.126-1086T>A variant in MPZ-MCS3.

To examine the effect of the c.126-1086T>A variant on in vitro enhancer activity of MPZ-MCS3, we cloned the wild-type and variant alleles (both forward and reverse orientations) upstream of a minimal promoter (pE1b) responsible for directing luciferase expression, transfected the resulting reporter constructs into cultured Schwann (S16) cells and oligodendrocytes (OliNeu) cells, and measured the luciferase activity relative to an internal renilla control. These studies revealed that the wild-type MPZ-MCS3 allele enhances luciferase expression by ~31.5- and ~7.2-fold (compared to a control reporter-gene construct lacking a cloned insert) in the forward and reverse orientations in S16 cells, respectively (Fig. 2B). In contrast, the c.126-1086T>A-containing MPZ-MCS3 allele enhances luciferase expression by ~12.7- and ~2.7-fold in the forward and reverse orientations in S16 cells, respectively (Fig. 2B). Thus, the c.126-1086T>A variant is associated with a 60–62% reduction of in vitro enhancer activity (depending on the orientation of the fragment in the reporter construct). Importantly, these data are consistent with previously-reported analyses on a similar construct with deleted SOX10 binding sites [16]. We also tested MPZ-MCS3 enhancer activity in OliNeu cells and found similar results as in S16 cells; the c.126-1086T>A variant is associated with a 32–42% reduction of in vitro enhancer activity, slightly less than observed in the S16 cells (Fig. 2C).

To determine the cell-type specificity of MPZ-MCS3, and to test the responsiveness of the wild-type and c.126-1086T>A alleles to SOX10, we tested the enhancer activity of each allele in SOX10-negative mouse motor neuron (MN-1) cells with, or without, co-transfection of a construct expressing SOX10 (Fig. 2D). First, neither wild-type nor c.126-1086T>A MPZ-MCS3 displayed significant enhancer potential in SOX10-negative cells. Second, the addition of 25 to 200 ng of a SOX10 expression construct dramatically increased enhancer potential (compared to the similarly-treated pE1b control vector), further suggesting that SOX10 specifically acts upon MPZ-MCS3. Interestingly, at each concentration of SOX10 expression construct, the mean value for the enhancer activity of the c.126-1086T>A allele (Var) was lower than that for the wild-type (Wt) allele (Fig. 2D); however, none of these experiments reached statistical significance.

c.126-1086T> A is associated with altered nuclear-protein binding

SOX10 and EGR2 have previously been shown to bind to MCS3, and deletion of the SOX10 consensus sequences ablate SOX10 binding [16]. We used electrophoretic mobility shift assays (EMSAs) to establish if the c.126-1086T>A variant is associated with altered binding of nuclear proteins (e.g., transcription factors) to MPZ-MCS3. Briefly, 32P-labeled double-stranded oligonucleotides (i.e., ‘probes’) containing the SOX10-binding consensus sequence within MPZ-MCS3 were incubated with nuclear extracts from S16 cells (pre-incubated with or without unlabeled oligonucleotides (i.e., ‘competitors’)), and then separated on a polyacrylamide gel. The probe containing the wild-type sequence appears to bind a single specific nuclear protein, while the probe containing the v c.126-1086T>A variant binds an additional nuclear protein (Fig. 2E). Notably, a competitor probe containing the variant sequence completely ablates binding of this additional nuclear protein, while an equivalent amount of the wild-type competitor did not. From this, we have shown that c.126-1086T>A alters the binding of nuclear proteins at MPZ-MCS3, potentially contributing to the reduced enhancer strength we observed in our in vitro studies.

MPZ-MCS3 directs reporter-gene expression in developing zebrafish embryos

We further studied the function of MPZ-MCS3 in vivo using a zebrafish model system. We hypothesized that if MPZ-MCS3 contributes to MPZ transcriptional regulatory control, this sequence interval would likely direct reporter-gene expression in myelinating cells in vivo. Specifically, this would include central nervous system oligodendrocytes and peripheral nervous system Schwann cells. Tol2-harboring transgene constructs containing either wild-type or c.126-1086T>A human MPZ-MCS3 cloned upstream of a c-fos minimal promoter and the EGFP gene were injected into two-celled zebrafish embryos. We selected all embryos expressing EGFP in mosaic G0 embryos to be raised and screened for germ-line transmission of the transgene. EGFP expression was documented at selected developmental time points (ranging from 24 hpf to 7 dpf) in the offspring of multiple independent founder transgenic-zebrafish for each construct.

Our analyses revealed strong EGFP expression in the telencephalon, midbrain tegmentum, lenses, and hindbrain (Fig. 3A, C, and E). At later stages (72 hpf and 7 dpf) expression became less abundant in the anterior CNS, yet remained present in the peripheral motor nerves; signal was also evident along the developing posterior lateral line nerve (arrow heads in Fig. 2C and E). This pattern largely correlates with endogenous mpz expression during zebrafish development—mpz is expressed in a dynamic spatial and temporal fashion from early stages in the lateral tegmentum, lens vesicles, optic nerves, hindbrain and anterior spinal cord [22], [23], [24]. Interestingly, mpz expression in zebrafish has been reported to be restricted to the CNS during early development [22], [25], whereas the mammalian orthologs are believed primarily to be expressed in Schwann cells [26].

Figure 3
MPZ-MCS3 directs reporter gene expression in relevant tissues in vivo.

In contrast to zebrafish harboring the wild-type enhancer, transgenic lines carrying c.126-1086T>A MPZ-MCS3 displayed markedly reduced EGFP expression in the forebrain, midbrain, and hindbrain (Fig. 3B, D and F), which was dramatically reduced at 48 hpf. Furthermore, descending motor nerves were not visible at this or other developmental time points in c.126-1086T>A MPZ-MCS3 zebrafish. While these differences may be due to the position of the inserted transgene and/or transgene copy number, they were observed in two wild-type and two c.126-1086T>A F1 zebrafish lines and are consistent with the above data showing decreased enhancer activity and altered nuclear-protein binding associated with the c.126-1086T>A variant (Fig. 2B-D). Both, mutant and wild-type enhancers displayed expression in the medulla oblongata and the spinal cord, potentially corresponding to the developing oligodendrocytic cells (Fig. 3B, DF and Fig. S1). In addition, we observed no overlap of reporter expression with acetylated tubulin (AcT) in the sympathetic nerves and probable oligodendrocytes in the spinal cord of 7 dpf fish carrying the wild-type MPZ-MCS3 (Fig. S1), which suggests that cells marked by this regulatory element are glial. Nevertheless, partial overlap of EGFP with AcT and mbp was visible in PLL ganglia (Fig. S1). This EGFP expression is consistent with glia ensheathing neuronal cells, nevertheless we cannot definitely exclude potential neuronal activity of the MPZ-MCS3 enhancer.

Discussion

In this study, we show that a naturally-occurring, rare, non-coding nucleotide variant modulates the activity of an MPZ-transcriptional enhancer. Specifically, we performed targeted genomic re-sequencing of a collection of patients with neurological disease, focusing our attention on predicted SOX10- and EGR2-binding sites within evolutionarily conserved non-coding regions of the MPZ gene. These efforts resulted in the identification of a rare variant (c.126-1086T>A) in a previously described SOX10-binding site [11], [16] in the first intron of MPZ. We characterized this variant in greater detail using a number of methods, including human population screening, comparative sequence analysis, in vitro reporter-gene assays in cultured Schwann and oligodendrocyte cells, electromobility shift assays (EMSAs), and in vivo reporter-gene expression in zebrafish. Our data indicate that the c.126-1086T>A variant resides at a nucleotide position that is highly conserved among mammals, is associated with decreased enhancer activity and altered nuclear-protein binding, and is situated in a genomic segment that directs reporter-gene expression in relevant tissues in developing zebrafish.

We were unable to clinically evaluate the transmitting parent (father) of the patient carrying this variant (BAB1733). Therefore, the c.126-1086T>A variant was not implicated in disease onset in humans. Thus, the development of a relevant vertebrate model (e.g., mouse) harboring c.126-1086T>A MPZ will be necessary to clarify the potential pathogenic role, if any, of this variant. However, our findings indicate that it would be prudent to screen these (as well as other) MPZ non-coding sequences for functional variants in human populations.

Our in vitro functional studies indicate that the wild-type genomic segment encompassing the c.126-1086T>A variant (MPZ-MCS3) directs reporter-gene expression in cultured Schwann and oligodendrocyte cells, does not display enhancer activity in SOX10-negative cells, is responsive to SOX10, and is bound by a nuclear protein—likely SOX10, which has been shown to bind this region in previous studies [11], [16]. Alternatively, c.126-1086T>A decreases enhancer activity in these same SOX10-positive cells and alters the binding of nuclear proteins. There are two possible interpretations of these data. First, it is conceivable the variant weakens the affinity for SOX10 and/or creates a novel protein binding site that competes with SOX10. Second, the variant could alter the nature of SOX10:EGR2 protein interactions in the nucleus; however, the fragment analyzed in EMSA analyses did not contain the EGR2 binding sequences. In any case, c.126-1086T>A MPZ represents a rare, functional variant this likely affects MPZ expression in vivo.

The studies we performed in zebrafish revealed that human MPZ-MCS3 directs reporter-gene expression in the hindbrain and spinal column in positions consistent with oligodendrocytes. These data are consistent with the established expression pattern of zebrafish mpz at 48 hpf and later [22]. Furthermore, human wild-type MPZ-MCS3 directs reporter-gene expression in distal regions of the descending spinal motor nerves, lateral line nerve, and sympathetic chain nerves. These findings are consistent with the expression of genes in Schwann cells, which myelinate all peripheral neurons. Interestingly, while MPZ is expressed in mammalian Schwann cells, mpz expression has not been detected in zebrafish Schwann cells up to 10 dpf by whole-mount in situ hybridization [22]. There are numerous possible explanations for this discrepancy. First, whole-mount in situ hybridization may not be sensitive enough to detect mpz expression in zebrafish Schwann cells. Second, mpz may be expressed at a later stage in zebrafish development, due to gene regulation by other elements (e.g., silencers) acting in a concerted fashion with the intron-1 enhancer. Third, mpz may not be expressed in zebrafish Schwann cells; in this case, the human wild-type MPZ-MCS3 transgene may direct expression of EGFP because sox10 is expressed in Schwann cells in zebrafish by 30–40 hpf [27]. Finally, the discrepancy in expression patterns between fish and terrestrial vertebrates may be due to the early, rapid evolution of the myelination process, which is crucial for vertebrate development. In higher vertebrates, the major requirement for adhesive molecules in the CNS may be encoded by other loci [28]. Indeed, this might explain the EGFP expression observed in glial cells of both the CNS and PNS in our studies (Figs. 3 and S1)—while the transcriptional vocabulary may be preserved between human and zebrafish, the tissue-specific requirements and corresponding expression patterns may differ.

The first intron of MPZ shares little sequence conservation between mammals and zebrafish (Fig. 1A); indeed, it is not possible to generate a sequence alignment between mammalian species and zebrafish in this region (data not shown). This observation is surprising given that human MPZ-MCS3 is functional in developing zebrafish. Such a discrepancy has been encountered with other non-coding genomic segments [29], [30], and it has been proposed that current algorithms for detecting sequence conservation between evolutionarily diverse species are not sufficiently sensitive to identify all functional non-coding sequences [31]. There are two possible explanations for the surprising lack of sequence conservation in light of our finding that human MPZ-MCS3 directs reporter-gene expression in developing zebrafish. First, there may be functional conservation between the orthologous regions in mammals and zebrafish, with sequence conservation falling below a threshold required for computational detection; it is notable that there are a number of SOX10-binding consensus sequences within this genomic region in zebrafish (data not shown). Second, MPZ-MCS3 may be functional in mammals, but the orthologous region may not be functional in non-mammalian vertebrates (e.g., zebrafish); thus, MPZ-MCS3 might be a mammalian lineage-specific transcriptional regulatory element. Each of these possibilities could be investigated further by analyzing overlapping segments of the first intron of the zebrafish mpz gene for enhancer activity in appropriate cell culture and in vivo model systems.

The complete sequencing of the human genome [32] and the initial analyses that have subsequently been performed [33] reveal the complexities of non-coding DNA, including sequence elements that regulate transcription. The study of functional non-coding sequences is becoming increasingly relevant for understanding the genetic basis of human disease. Yet, major challenges remain both in identifying such sequences and in establishing if variants residing in such sequences are phenotypically relevant. While we were unable to implicate the MPZ intronic variant in disease onset, the experimental pursuits described here attempted to address the above-mentioned challenges. First, comparative sequencing coupled with other bioinformatic-based analyses were used to prioritize the more detailed examination of candidate functional non-coding sequences. Second, a variant detected in a human population was studied by both in vitro and in vivo assays in an attempt to experimentally establish the functional consequences of such variation. While in vitro reporter-gene assays are relatively routine, they do not provide broad biological insight into the role of the non-coding sequences being studied (or of the variants residing therein). Our use of zebrafish to study the wild-type and variant forms of MPZ-MCS3 nicely illustrates the value of an in vivo assay system, particularly since certain mammalian transcriptional regulatory elements are known to function in zebrafish. However, the zebrafish system also has limitations, such as for studying sequences that function in a mammalian- or human-specific fashion and for capturing quantitative data about reporter-gene expression. For the latter limitation, developing a zebrafish system for quantitatively measuring allelic differences in enhancer activity would be a major step toward improving our ability to characterize the functional consequences of non-coding variants and to establish their roles in human disease.

Methods

Ethics Statement

All of the studies performed herein were performed under IRB and ACUC approval from the National Institutes of Health (NHGRI), Baylor College of Medicine, and Johns Hopkins University.

Comparative sequence analysis

Two complementary methods were used to identify multi-species conserved sequences (MCSs) in the genomic region encompassing the human MPZ gene. First, MPZ-containing bacterial artificial chromosomes derived from the following species were isolated and sequenced as described [34]: lemur (GenBank No. AC157839), dog (GenBank No. AC158443), cow (GenBank No. AC158441), hedgehog (GenBank No. AC157618), and armadillo (GenBank No. AC157449). Sequences encompassing MPZ in human [University of California at Santa Cruz (UCSC) Human Genome Browser March 2006 assembly, chr1:159521864-159550790], mouse (UCSC Mouse Genome Browser August 2005 assembly, chr1:170969846-171282175), rat (UCSC Rat Genome Browser June 2003 assembly, chr13:86986762-87476861), and zebrafish (UCSC Zebrafish Genome Browser July 2007 assembly, chr2:39940779-40174778) were obtained from the UCSC Genome Browser (genome.ucsc.edu). All sequences were analyzed using MultiPipMaker [pipmaker.bx.psu.edu/cgi-bin/multipipmaker [35] to yield a multi-sequence alignment (in the form of an acgt file), which was subsequently analyzed using ExactPlus [36] to identify segments at least 5 bp long and 100% conserved in at least 6 species. Second, the UCSC Human Genome Browser (March 2006 build) was used to identify non-coding regions in and around the MPZ gene (chr1:159521864-159550790) with a PhastCons score of at least 350. SOX10- and EGR2-binding sites were identified within the ExactPlus- and PhastCons-detected MCSs using the PATCH algorithm of the TRANSFAC database [37]; for this analysis, a minimum site length of 6 bp (tolerating zero mismatches with known binding sites) and a lower score boundary of 87.5 were required.

Patient DNA samples and variant screening

DNA samples were obtained from patients diagnosed with neurological disease based on an examination by a collaborating physician. For genetic analyses, genomic DNA was purified from patient-derived peripheral blood or lymphoblastoid cell lines using standard procedures. All studies were performed with the approval of the appropriate Institutional Review Board.

Each genomic region of interest was screened for sequence variants by PCR amplification and direct sequencing of the amplified DNA segment. Specifically, oligonucleotide primers (sequences available upon request) were designed to amplify each region. PCR assays contained 1.5 µM of each primer, 0.2 µM dNTPs, 1.5 µM MgCl2, 1 unit AmpliTaq DNA Polymerase (Applied Biosystems, Foster City, CA), 1X of the manufacturer's buffer, and 200 ng of genomic DNA. Thermal cycling consisted of an initial denaturation for 2 minutes at 93°C, followed by 40 cycles of 93°C for 10 seconds, 55°C for 5 seconds, and 72°C for 30 seconds. A final incubation at 72°C was then performed for 7 minutes. Following electrophoretic separation on a 1% agarose gel, the PCR products were excised and purified using the QIAquick Gel Extraction Kit (Qiagen, Valencia, CA). DNA sequencing was performed using BigDye terminator chemistry. Reactions (20 µl total) consisting of 8 µl BigDye mix, 0.5 µl sequencing primer (at 25 µM), 6.5 µl water, and 5 µl PCR product (at ~50 ng/µl) were subjected to 30 cycles of 92°C for 20 seconds, 55°C for 10 seconds, and 60°C for 4 minutes. Subsequently, unincorporated nucleotides were removed using CentriSep 8 column strips (Princeton Separations, Adelphia, NJ), and the final products were analyzed on a model 3100 DNA sequencing instrument (Applied Biosystems, Foster City, CA). Data were extracted and analyzed using Sequencing Analysis software (Applied Biosystems), and the resulting sequences were aligned with Sequencher (GeneCodes, Ann Arbor, MI). Genotyping for the c.126-1086T>A allele was performed by direct sequencing of PCR products (as above) amplified from DNA samples from a North American population [38].

Reporter constructs

Reporter constructs for assaying enhancer activity and gene expression were generated using Gateway cloning technology (Invitrogen, Carlsbad, CA). Briefly, PCR primers containing flanking attB sites (on their 5′ ends) were designed to amplify each MPZ-MCS from human DNA. To obtain both the wild-type and c.126-1086T>A-containing alleles for the MPZ-MCS3 (see Results), PCR amplification was performed using a DNA sample from the heterozygous patient (BAB1733). PCR products containing each allele were then recombined into the pDONR221 vector (according to the manufacturer's instructions) to yield appropriate entry clones; the insert of each selected entry clone was sequenced to identify a clone containing each allele with no PCR-induced mutations. Subsequently, plasmid DNA purified from each entry clone was recombined with either the pLGF-E1b (for luciferase expression in cultured cells) [36] or pXIG-cfos-EGFP [for enhanced green fluorescent protein (EGFP) expression in developing zebrafish embryos [30]] destination vectors according to the manufacturer's instructions. Each resulting reporter construct was analyzed by restriction enzyme digestion (with BsrGI) to confirm the presence of an appropriately-sized insert.

Assaying in vitro enhancer activity

Immortalized rat Schwann (S16) cells and mouse motor neurons (MN1) were cultured in Dulbecco's Modified Eagle Medium (DMEM; Invitrogen) supplemented with 10% fetal bovine serum (FBS; Invitrogen) and 1X glutamine, as previously reported [39]. Immortalized mouse oligodendrocyte (OliNeu) cells were cultured as previously reported [40]. Cells (5×104) were placed into each well of a 96-well culture plate and transfected with luciferase reporter constructs (see above) using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA). For each reaction, 0.25 µl Lipofectamine 2000 and 25 µl OptiMEM I minimal growth medium (Invitrogen) were combined and incubated at room temperature for 10 minutes. The purified luciferase reporter construct (200 ng) [or the equivalent volume of water (in the case of DNA-negative controls)] and 2 ng of purified pCMV-RL vector (a renilla-expression construct that served as an internal control; Promega, Madison, WI) were diluted in 25 µl OptiMEM I and then combined with the Lipofectamine-OptiMEM I mixture. The ~50-µl reactions were incubated at room temperature for 20 minutes and then added to a single well of the 96-well culture plate containing cells. After a 3-hour incubation at 37°C, the medium was aspirated, and normal growth medium was added. The SOX10 expression construct was obtained from Origene (Rockville, MD).

Following a 48-hour incubation at 37°C, cells were washed with 1X PBS and lysed at room temperature using 1X Passive Lysis Buffer (Promega). An aliquot (4 µl) of the resulting cell lysate was transferred to a white polystyrene 96-well assay plate (Corning Inc., Corning, NY). Luciferase and renilla activities were measured using the Dual Luciferase Reporter 1000 Assay System (Promega) and a model Centro LB 960 luminometer (Berthold Technologies, Bad Wildbad, Germany). Each experiment was performed at least 16 times. In each case, the ratio of luciferase to renilla activity and the increase in this ratio over that measured for pLGF-E1b with no insert (indicated as ‘fold increase in luciferase activity’) were calculated. The mean (bar heights in Fig. 2) and standard deviation (error bars in Fig. 2) were determined using standard calculations.

Assaying nuclear-protein binding

Complementary pairs of oligonucleotides (sequences available upon request) specific for the genomic DNA encompassing MPZ intron 1 SOX10-consensus sequence (see Results) were annealed and end-labeled with [γ-32P]ATP (PerkinElmer, Boston, MA) using 10 units of T4 polynucleotide kinase (Promega). The radiolabeled products (probes) were purified using an Illustra™ Microspin™ G-25 column (GE Healthcare, Piscataway, NJ). The ionizing radiation of each probe was measured using a liquid scintillation counter (L2 6500, Beckman Coulter, Fullerton, CA). Nuclear extracts from S16 cells, prepared using a Nuclear Extraction Kit (Cayman Chemical, Ann Arbor, MI), were incubated in a 20-µl reaction with or without unlabeled double-stranded oligonucleotides (competitor) in the presence of DNA-binding buffer (Promega) for 10 min at room temperature. Samples were then incubated with the above 32P-labeled probes (17.5 fmol/sample) for 20 min at room temperature. The DNA/protein complexes were separated on a 6% TBE DNA Retardation gel (Invitrogen) at room temperature, dried at 80°C for 1 hr, and visualized using a Fujifilm FLA-5000 image analyzer (FujiFilm, Tokyo, Japan).

Gene-expression studies in zebrafish

Zebrafish were raised and bred using standard protocols, including maintaining staged embryos at 28°C [41], [42]. EGFP-expression constructs (see above) were injected into AB background G0 embryos (n≥200) as described [30], [43]. Injected embryos were evaluated for EGFP expression between 24 hours post fertilization (hpf) and 7 days post fertilization (dpf). Embryos showing consistent EGFP expression were selected and allowed to mature and subsequently crossed, which permitted germline transmission and better evaluation of EGFP expression. Embryos were imaged using a Carl Zeiss Lumar V12 Stereo microscope with AxioVision software (version 4.5).

7dpf embryos were anesthetized with tricaine (10 µg/ml) in embryo medium [42] and fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS; pH 7.2) for 2 hours. They were then rinsed four times in PBST (PBS/0.1% Triton X-100), incubated in Proteinase K for 1 h at room temperature, washed 5×5 minutes in PBST, and incubated for 2 hours in blocking solution (10% goat serum, 1% bovine serum albumin [BSA], in PBST). Embryos were then incubated overnight at room temperature in primary antibody, rinsed 6×45 minutes in PBST 1% goat serum, and incubated overnight at room temperature in secondary antibody. They were then rinsed 5×10 minutes in PBST and transferred to 50% glycerol in PBS. For primary antibodies, anti-acetylated tubulin (Sigma) was used at 1[ratio]100, anti-gfp (Invitrogen) was used at 1[ratio]2,000. Alexa Fluor 488 and 555 (Invitrogen) were used as secondary antibodies (1[ratio]1000).

Supporting Information

Figure S1

MPZ-MCS3 wild-type transgenic zebrafish embryos (7dpf) stained for EGPF (A-K) and acetylated tubulin (AcT in B,C,E,F,H, and I) and MBP (K and L). Panels A-C and J-K display the lateral view at the PLL ganglion region. Panels D-F represent lateral views showing trunk expression, whereas panels G-I show sympathetic chain expression from the ventro-lateral view; anterior is to the left; white arrowheads indicate PLL; white arrows indicate probable oligodendrocytes and blue arrows point at cells expressing EGFP but not AcT in the sympathetic chain nerves.

(9.167 MB TIF)

Acknowledgments

We are indebted to the patients and their families for participation in these studies. We also thank Shih-Queen Lee-Lin for technical assistance, Kensuke Shiga and Mustafa Saifi for helping with the acquisition of patient samples, Larry Brody for providing control human DNA samples, Richard Quarles for providing S16 cells, and Asako Takanohashi and Adeline Vanderver for OliNeu cells.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported in part by the Intramural Research Program of the National Human Genome Research Institute (National Institutes of Health), a fellowship (AA) and grant (JRL) from the Charcot-Marie-Tooth Association, grant R01GM071648 from the National Institute of General Medical Sciences (ASM), grant R01NS062972 (ASM) from the National Institute of Neurological Diseases and Stroke, and grant R00NS060983 from the National Institute of Neurological Diseases and Stroke (AA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Inouye H, Tsuruta H, Sedzik J, Uyemura K, Kirschner DA. Tetrameric assembly of full-sequence protein zero myelin glycoprotein by synchrotron x-ray scattering. Biophys J. 1999;76:423–437. [PubMed]
2. Shapiro L, Doyle JP, Hensley P, Colman DR, Hendrickson WA. Crystal structure of the extracellular domain from P0, the major structural protein of peripheral nerve myelin. Neuron. 1996;17:435–449. [PubMed]
3. Thompson AJ, Cronin MS, Kirschner DA. Myelin protein zero exists as dimers and tetramers in native membranes of Xenopus laevis peripheral nerve. J Neurosci Res. 2002;67:766–771. [PubMed]
4. Warner LE, Hilz MJ, Appel SH, Killian JM, Kolodry EH, et al. Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination. Neuron. 1996;17:451–460. [PubMed]
5. Hayasaka K, Himoro M, Sato W, Takada G, Uyemura K, et al. Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene. Nat Genet. 1993;5:31–34. [PubMed]
6. Roa BB, Warner LE, Garcia CA, Russo D, Lovelace R, et al. Myelin protein zero (MPZ) gene mutations in nonduplication type 1 Charcot-Marie-Tooth disease. Hum Mutat. 1996;7:36–45. [PubMed]
7. Su Y, Brooks DG, Li L, Lepercq J, Trofatter JA, et al. Myelin protein zero gene mutated in Charcot-Marie-tooth type 1B patients. Proc Natl Acad Sci U S A. 1993;90:10856–10860. [PubMed]
8. Inoue K, Khajavi M, Ohyama T, Hirabayashi S, Wilson J, et al. Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. Nat Genet. 2004;36:361–369. [PubMed]
9. Martini R, Zielasek J, Toyka KV, Giese KP, Schachner M. Protein zero (P0)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. Nat Genet. 1995;11:281–286. [PubMed]
10. Brown AM, Lemke G. Multiple regulatory elements control transcription of the peripheral myelin protein zero gene. J Biol Chem. 1997;272:28939–28947. [PubMed]
11. LeBlanc SE, Jang SW, Ward RM, Wrabetz L, Svaren J. Direct regulation of myelin protein zero expression by the Egr2 transactivator. J Biol Chem. 2006;281:5453–5460. [PubMed]
12. Lemke G, Lamar E, Patterson J. Isolation and analysis of the gene encoding peripheral myelin protein zero. Neuron. 1988;1:73–83. [PubMed]
13. Warner LE, Mancias P, Butler IJ, McDonald CM, Keppen L, et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet. 1998;18:382–384. [PubMed]
14. Jang SW, Svaren J. Induction of myelin protein zero by early growth response 2 through upstream and intragenic elements. J Biol Chem. 2009;284:20111–20120. [PubMed]
15. Jones EA, Jang SW, Mager GM, Chang LW, Srinivasan R, et al. Interactions of Sox10 and Egr2 in myelin gene regulation. Neuron Glia Biol. 2007;3:377–387. [PMC free article] [PubMed]
16. LeBlanc SE, Ward RM, Svaren J. Neuropathy-associated Egr2 mutants disrupt cooperative activation of myelin protein zero by Egr2 and Sox10. Mol Cell Biol. 2007;27:3521–3529. [PMC free article] [PubMed]
17. Warner LE, Svaren J, Milbrandt J, Lupski JR. Functional consequences of mutations in the early growth response 2 gene (EGR2) correlate with severity of human myelinopathies. Hum Mol Genet. 1999;8:1245–1251. [PubMed]
18. Bondurand N, Girard M, Pingault V, Lemort N, Dubourg O, et al. Human Connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor SOX10. Hum Mol Genet. 2001;10:2783–2795. [PubMed]
19. Ionasescu VV, Searby C, Ionasescu R, Neuhaus IM, Werner R. Mutations of the noncoding region of the connexin32 gene in X-linked dominant Charcot-Marie-Tooth neuropathy. Neurology. 1996;47:541–544. [PubMed]
20. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, et al. The human genome browser at UCSC. Genome Res. 2002;12:996–1006. [PubMed]
21. Peirano RI, Wegner M. The glial transcription factor Sox10 binds to DNA both as monomer and dimer with different functional consequences. Nucleic Acids Res. 2000;28:3047–3055. [PMC free article] [PubMed]
22. Brosamle C, Halpern ME. Characterization of myelination in the developing zebrafish. Glia. 2002;39:47–57. [PubMed]
23. Kazakova N, Li H, Mora A, Jessen KR, Mirsky R, et al. A screen for mutations in zebrafish that affect myelin gene expression in Schwann cells and oligodendrocytes. Dev Biol. 2006;297:1–13. [PubMed]
24. Monk KR, Naylor SG, Glenn TD, Mercurio S, Perlin JR, et al. A G protein-coupled receptor is essential for Schwann cells to initiate myelination. Science. 2009;325:1402–1405. [PMC free article] [PubMed]
25. Schweitzer J, Becker T, Schachner M, Nave KA, Werner H. Evolution of myelin proteolipid proteins: gene duplication in teleosts and expression pattern divergence. Mol Cell Neurosci. 2006;31:161–177. [PubMed]
26. Quarles RH. Myelin sheaths: glycoproteins involved in their formation, maintenance and degeneration. Cell Mol Life Sci. 2002;59:1851–1871. [PubMed]
27. Dutton KA, Pauliny A, Lopes SS, Elworthy S, Carney TJ, et al. Zebrafish colourless encodes sox10 and specifies non-ectomesenchymal neural crest fates. Development. 2001;128:4113–4125. [PubMed]
28. Yoshida M, Colman DR. Parallel evolution and coexpression of the proteolipid proteins and protein zero in vertebrate myelin. Neuron. 1996;16:1115–1126. [PubMed]
29. Antonellis A, Huynh JL, Lee-Lin SQ, Vinton RM, Renaud G, et al. Identification of neural crest and glial enhancers at the mouse Sox10 locus through transgenesis in zebrafish. PLoS Genet. 2008;4:e1000174. [PMC free article] [PubMed]
30. Fisher S, Grice EA, Vinton RM, Bessling SL, McCallion AS. Conservation of RET regulatory function from human to zebrafish without sequence similarity. Science. 2006;312:276–279. [PubMed]
31. McGaughey DM, Vinton RM, Huynh J, Al-Saif A, Beer MA, et al. Metrics of sequence constraint overlook regulatory sequences in an exhaustive analysis at phox2b. Genome Res. 2008;18:252–260. [PubMed]
32. Consortium IHGS. Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931–945. [PubMed]
33. ENCODE PC. The ENCODE (ENCyclopedia Of DNA Elements) Project. Science. 2004;306:636–640. [PubMed]
34. Thomas JW, Touchman JW, Blakesley RW, Bouffard GG, Beckstrom-Sternberg SM, et al. Comparative analyses of multi-species sequences from targeted genomic regions. Nature. 2003;424:788–793. [PubMed]
35. Elnitski L, Riemer C, Schwartz S, Hardison R, Miller W. PipMaker: a World Wide Web server for genomic sequence alignments. Curr Protoc Bioinformatics Chapter. 2003;10:Unit 10 12. [PubMed]
36. Antonellis A, Bennett WR, Menheniott TR, Prasad AB, Lee-Lin SQ, et al. Deletion of long-range sequences at Sox10 compromises developmental expression in a mouse model of Waardenburg-Shah (WS4) syndrome. Hum Mol Genet. 2006;15:259–271. [PubMed]
37. Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 2003;31:374–378. [PMC free article] [PubMed]
38. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 1995;11:198–200. [PubMed]
39. Toda K, Small JA, Goda S, Quarles RH. Biochemical and cellular properties of three immortalized Schwann cell lines expressing different levels of the myelin-associated glycoprotein. J Neurochem. 1994;63:1646–1657. [PubMed]
40. Jung M, Kramer E, Grzenkowski M, Tang K, Blakemore W, et al. Lines of murine oligodendroglial precursor cells immortalized by an activated neu tyrosine kinase show distinct degrees of interaction with axons in vitro and in vivo. Eur J Neurosci. 1995;7:1245–1265. [PubMed]
41. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. Dev Dyn. 1995;203:253–310. [PubMed]
42. Westerfield M. Eugene, OR: University of Oregon Press; 2000. The Zebrafish Book.
43. Fisher S, Grice EA, Vinton RM, Bessling SL, Urasaki A, et al. Evaluating the biological relevance of putative enhancers using Tol2 transposon-mediated transgenesis in zebrafish. Nat Protoc. 2006;1:1297–1305. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science